6MK4

Solution NMR structure of spider toxin analogue [E17K]ProTx-II

  • Classification: TOXIN
  • Organism(s): Thrixopelma pruriens
  • Mutation(s): Yes 

  • Deposited: 2018-09-25 Released: 2018-12-19 
  • Deposition Author(s): Schroeder, C.I.
  • Funding Organization(s): National Health and Medical Research Council (NHMRC, Australia), Australian Research Council (ARC)

Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 50 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation   3D Report Full Report


This is version 1.4 of the entry. See complete history


Literature

Peptide-Membrane Interactions Affect the Inhibitory Potency and Selectivity of Spider Toxins ProTx-II and GpTx-1.

Lawrence, N.Wu, B.Ligutti, J.Cheneval, O.Agwa, A.J.Benfield, A.H.Biswas, K.Craik, D.J.Miranda, L.P.Henriques, S.T.Schroeder, C.I.

(2019) ACS Chem Biol 14: 118-130

  • DOI: https://doi.org/10.1021/acschembio.8b00989
  • Primary Citation of Related Structures:  
    6MK4, 6MK5

  • PubMed Abstract: 

    Gating modifier toxins (GMTs) from spider venom can inhibit voltage gated sodium channels (Na V s) involved in pain signal transmission, including the Na V 1.7 subtype. GMTs have a conserved amphipathic structure that allow them to interact with membranes and also with charged residues in regions of Na V that are exposed at the cell surface. ProTx-II and GpTx-1 are GMTs able to inhibit Na V 1.7 with high potency, but they differ in their ability to bind to membranes and in their selectivity over other Na V subtypes. To explore these differences and gain detailed information on their membrane-binding ability and how this relates to potency and selectivity, we examined previously described Na V 1.7 potent/selective GpTx-1 analogues and new ProTx-II analogues designed to reduce membrane binding and improve selectivity for Na V 1.7. Our studies reveal that the number and type of hydrophobic residues as well as how they are presented at the surface determine the affinity of ProTx-II and GpTx-1 for membranes and that altering these residues can have dramatic effects on Na V inhibitory activity. We demonstrate that strong peptide-membrane interactions are not essential for inhibiting Na V 1.7 and propose that hydrophobic interactions instead play an important role in positioning the GMT at the membrane surface proximal to exposed Na V residues, thereby affecting peptide-channel interactions. Our detailed structure-activity relationship study highlights the challenges of designing GMT-based molecules that simultaneously achieve high potency and selectivity for Na V 1.7, as single mutations can induce local changes in GMT structure that can have a major impact on Na V -inhibitory activity.


  • Organizational Affiliation

    Institute for Molecular Bioscience , The University of Queensland , Brisbane , Queensland 4072 , Australia.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Beta/omega-theraphotoxin-Tp2a30Thrixopelma pruriensMutation(s): 1 
UniProt
Find proteins for P83476 (Thrixopelma pruriens)
Explore P83476 
Go to UniProtKB:  P83476
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP83476
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 50 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Health and Medical Research Council (NHMRC, Australia)AustraliaAPP1080405
Australian Research Council (ARC)AustraliaFT160100055
Australian Research Council (ARC)AustraliaFT150100398
Australian Research Council (ARC)AustraliaFL150100146

Revision History  (Full details and data files)

  • Version 1.0: 2018-12-19
    Type: Initial release
  • Version 1.1: 2019-04-03
    Changes: Data collection, Database references
  • Version 1.2: 2020-01-01
    Changes: Author supporting evidence, Data collection
  • Version 1.3: 2023-06-14
    Changes: Database references, Other
  • Version 1.4: 2024-10-09
    Changes: Data collection, Database references, Structure summary